{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:11:50Z","timestamp":1780978310431,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T00:00:00Z","timestamp":1492732800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11914-017-0361-4","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T06:44:28Z","timestamp":1492757068000},"page":"171-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease"],"prefix":"10.1007","volume":"15","author":[{"given":"Matthew R.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad W.","family":"Aref","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"361_CR1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RGG Russell","year":"2011","unstructured":"Russell RGG. Bisphosphonates: the first 40 years. Bone. 2011;49:2\u201319.","journal-title":"Bone"},{"key":"361_CR2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ki.1975.70","volume":"8","author":"U Troehler","year":"1975","unstructured":"Troehler U, Bonjour J-P, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int. 1975;8:6\u201313.","journal-title":"Kidney Int"},{"key":"361_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","volume":"49","author":"PD Miller","year":"2011","unstructured":"Miller PD. The kidney and bisphosphonates. Bone. 2011;49:77\u201381.","journal-title":"Bone"},{"key":"361_CR4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2006.12.006","volume":"558","author":"K Tamura","year":"2007","unstructured":"Tamura K, Suzuki Y, Matsushita M, Fujii H, Miyaura C, Aizawa S, et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol. 2007;558:159\u201366.","journal-title":"Eur J Pharmacol"},{"key":"361_CR5","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/jbmr.2089","volume":"29","author":"SM Moe","year":"2014","unstructured":"\u2022 Moe SM, Chen NX, Newman CL, Gattone II VH, Organ JM, Chen X, et al. A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. J Bone Miner Res. 2014;29:902\u201310. One of the few studies to examine effects of bisphosphonates on bone remodeling and mechanics in animals with compromised kidney function.","journal-title":"J Bone Miner Res"},{"key":"361_CR6","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.ki.5001841","volume":"70","author":"PA Price","year":"2006","unstructured":"Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int. 2006;70:1577\u201383.","journal-title":"Kidney Int"},{"key":"361_CR7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bone.2011.03.774","volume":"49","author":"FH Ebetino","year":"2011","unstructured":"Ebetino FH, Hogan A-ML, Sun S, Tsoumpra MK, Duan X, Triffitt JT, et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone. 2011;49:20\u201333.","journal-title":"Bone"},{"key":"361_CR8","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RGG Russell","year":"2008","unstructured":"Russell RGG, Watts N, Ebetino FH, Rogers M. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008;19:733\u201359.","journal-title":"Osteoporos Int"},{"key":"361_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers MJ, Crockett JC, Coxon FP, M\u00f6nkk\u00f6nen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone. 2011;49:34\u201341.","journal-title":"Bone"},{"key":"361_CR10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1517\/17425255.4.11.1371","volume":"4","author":"MR Allen","year":"2008","unstructured":"Allen MR. Skeletal accumulation of bisphosphonates: implications for osteoporosis treatment. Expert Opin Drug Metab Toxicol. 2008;4:1371\u20138.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"361_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"J Lin","year":"1996","unstructured":"Lin J. Bisphosphonates: a review of their pharmacokinetic properties. Bone. 1996;18:75.","journal-title":"Bone"},{"key":"361_CR12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0090-9556(25)08706-9","volume":"20","author":"JH Lin","year":"1992","unstructured":"Lin JH, Chen IW, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos. 1992;20:473\u20138.","journal-title":"Drug Metab Dispos"},{"key":"361_CR13","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0090-9556(25)06818-7","volume":"23","author":"T Usui","year":"1995","unstructured":"Usui T, Watanabe T, Higuchi S. Pharmacokinetics of YM175, a new bisphosphonate, in rats and dogs. Drug Metab Dispos. 1995;23:1214\u20139.","journal-title":"Drug Metab Dispos"},{"key":"361_CR14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"L Plotkin","year":"1999","unstructured":"Plotkin L, Weinstein R, Parfitt A, Roberson P, Manolagas S, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363\u201374.","journal-title":"J Clin Invest"},{"key":"361_CR15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bone.2006.02.060","volume":"39","author":"L Plotkin","year":"2006","unstructured":"Plotkin L, Manolagas S, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts\/osteocytes with novel analogs. Bone. 2006;39:443\u201352.","journal-title":"Bone"},{"key":"361_CR16","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/8756-3282(96)00182-2","volume":"19","author":"P Masarachia","year":"1996","unstructured":"Masarachia P, Weinreb M, Balena R. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 1996;19:281\u201390.","journal-title":"Bone"},{"key":"361_CR17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/154405910708601102","volume":"86","author":"D Kimmel","year":"2007","unstructured":"Kimmel D. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022.","journal-title":"J Dent Res"},{"key":"361_CR18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1359\/jbmr.080501","volume":"23","author":"R Fuchs","year":"2008","unstructured":"Fuchs R, Phipps R. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Min Res. 2008;23:1689\u201397.","journal-title":"J Bone Min Res"},{"key":"361_CR19","first-page":"23","volume":"106","author":"U Troehler","year":"1985","unstructured":"Troehler U, Bonjour JP, Fleisch H. Renal transport of bisphosphonates: accumulation by renal cortical slices enhanced by calcium phosphate ions. J Lab Clin Med. 1985;106:23\u20139.","journal-title":"J Lab Clin Med"},{"key":"361_CR20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","volume":"97","author":"T Pfister","year":"2005","unstructured":"Pfister T, Atzpodien E, Bohrmann B, Bauss F. Acute renal effects of intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol. 2005;97:374\u201381.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"361_CR21","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.vascn.2012.12.001","volume":"68","author":"R Bergner","year":"2013","unstructured":"\u2022 Bergner R, Siegrist B, Kr\u00e4nzlin B, Gretz N, Faust H, Pfister T. Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function. J Pharmacol Toxicol Methods. 2013;68:225\u201330. Excellent study that examines renal handing of bisphosphonates in animals with compromised kidney function.","journal-title":"J Pharmacol Toxicol Methods"},{"key":"361_CR22","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.tiv.2008.01.006","volume":"22","author":"A L\u00fche","year":"2008","unstructured":"L\u00fche A, K\u00fcnkele K-P, Haiker M, Schad K, Zihlmann C, Bauss F, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicol in Vitro. 2008;22:899\u2013909.","journal-title":"Toxicol in Vitro"},{"key":"361_CR23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/01926233890171P104","volume":"17","author":"CL Alden","year":"1989","unstructured":"Alden CL, Parker RD, Eastman DF. Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol Pathol. 1989;17:27\u201332.","journal-title":"Toxicol Pathol"},{"key":"361_CR24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0300-483X(03)00257-9","volume":"191","author":"T Pfister","year":"2003","unstructured":"Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology. 2003;191:159\u201367.","journal-title":"Toxicology"},{"key":"361_CR25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0773.1997.tb01964.x","volume":"80","author":"JR Green","year":"1997","unstructured":"Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacology & toxicology. 1997;80:225\u201330.","journal-title":"Pharmacology & toxicology"},{"key":"361_CR26","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945\u201353.","journal-title":"Kidney Int"},{"key":"361_CR27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1681\/ASN.2010121253","volume":"23","author":"HH Malluche","year":"2012","unstructured":"Malluche HH, Porter DS, Monier-Faugere M-C, Mawad H, Pienkowski D. Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol. 2012;23:525\u201332.","journal-title":"J Am Soc Nephrol"},{"key":"361_CR28","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/jbmr.5650010503","volume":"1","author":"DL Andress","year":"1986","unstructured":"Andress DL, Maloney NA, Endres DB, Sherrard DJ. Aluminum-associated bone disease in chronic renal failure: high prevalence in a long-term dialysis population. J Bone Miner Res. 1986;1:391\u20138.","journal-title":"J Bone Miner Res"},{"key":"361_CR29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster DW, Compston JE, Drezner MK, Glorieux FH, Kanis JA, Malluche H, et al. Standardized nomenclature, symbols, and units for bone histomorphometry. J Bone Miner Res. 2013;28:2\u201317.","journal-title":"J Bone Miner Res"},{"key":"361_CR30","doi-asserted-by":"crossref","unstructured":"Recker R, Kimmel D, Dempster D, Weinstein R, Wronski T, Burr DB. Issues in Histomorphometry. Bone. 2011;49:955\u201364.","DOI":"10.1016\/j.bone.2011.07.017"},{"key":"361_CR31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2008.646","volume":"75","author":"KA Lomashvili","year":"2009","unstructured":"\u2022 Lomashvili KA, Monier-Faugere M-C, Wang X, Malluche HH, O'Neill WC. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009;75:617\u201325. One of the few studies to examine effects of bisphosphonates on vascular calcification in animals with compromised kidney function.","journal-title":"Kidney Int"},{"key":"361_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/ki.2008.180","volume":"74","author":"J Jokihaara","year":"2008","unstructured":"Jokihaara J, P\u00f6rsti IH, K\u00f6\u00f6bi P, Jolma PM, Mustonen JT, Saha HHT, et al. Treatment of experimental renal osteodystrophy with pamidronate. Kidney Int. 2008;74:319\u201327.","journal-title":"Kidney Int"},{"key":"361_CR33","first-page":"45","volume":"54","author":"Z Geng","year":"2000","unstructured":"Geng Z, Monier-Faugere MC, Bauss F, Malluche HH. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure. Clin Nephrol. 2000;54:45\u201353.","journal-title":"Clin Nephrol"},{"key":"361_CR34","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00198-012-2103-x","volume":"24","author":"MR Allen","year":"2012","unstructured":"Allen MR, Chen NX, Gattone VH, Chen X, Carr AJ, LeBlanc P, et al. Skeletal effects of zoledronic acid in an animal model of chronic kidney disease. Osteoporos Int. 2012;24:1471\u201381.","journal-title":"Osteoporos Int"},{"key":"361_CR35","first-page":"174","volume":"5","author":"A Tomat","year":"2005","unstructured":"Tomat A, Gamba CA, Mandalunis P, De Grandi MC, Somoza J, Friedman S, et al. Changes in bone volume and bone resorption by olpadronate treatment in an experimental model of uremic bone disease. J Musculoskelet Nueronal Interact. 2005;5:174\u201381.","journal-title":"J Musculoskelet Nueronal Interact"},{"key":"361_CR36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2015.04.021","volume":"77","author":"CL Newman","year":"2015","unstructured":"Newman CL, Chen NX, Smith E, Smith M, Brown D, Moe SM, et al. Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions. Bone. 2015;77:50\u20136.","journal-title":"Bone"},{"key":"361_CR37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1359\/jbmr.1998.13.8.1213","volume":"13","author":"AM Parfitt","year":"1998","unstructured":"Parfitt AM. A structural approach to renal bone disease. J Bone Miner Res. 1998;13:1213\u201320.","journal-title":"J Bone Miner Res"},{"key":"361_CR38","doi-asserted-by":"crossref","first-page":"e99262","DOI":"10.1371\/journal.pone.0099262","volume":"9","author":"CL Newman","year":"2014","unstructured":"Newman CL, Moe SM, Chen NX, Hammond MA, Wallace JM, Nyman JS, et al. Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease. PLoS One. 2014;9:e99262.","journal-title":"PLoS One"},{"key":"361_CR39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00198-014-2978-9","volume":"26","author":"MR Allen","year":"2014","unstructured":"Allen MR, Newman CL, Chen N, Granke M, Nyman JS, Moe SM. Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease. Osteoporos Int. 2014;26:977\u201385.","journal-title":"Osteoporos Int"},{"key":"361_CR40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bone.2010.10.159","volume":"49","author":"MR Allen","year":"2011","unstructured":"Allen MR, Burr DB. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don\u2019t know. Bone. 2011;49:56\u201365.","journal-title":"Bone"},{"key":"361_CR41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00467-010-1660-5","volume":"26","author":"D-C Fischer","year":"2010","unstructured":"Fischer D-C, Jensen C, Rahn A, Salewski B, Kundt G, Behets GJ, et al. Ibandronate affects bone growth and mineralization in rats with normal and reduced renal function. Pediatr Nephrol. 2010;26:111\u20137.","journal-title":"Pediatr Nephrol"},{"key":"361_CR42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1681\/ASN.2007080854","volume":"19","author":"SM Moe","year":"2008","unstructured":"Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"361_CR43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","volume":"21","author":"PA Price","year":"2001","unstructured":"Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001;21:817\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-017-0361-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0361-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:31:57Z","timestamp":1750203117000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-017-0361-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s11914-017-0361-4","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}